Gufic Biosciences Limited

rs,

308/LG/SE/NOV/2025/GBSL November 14, 2025 To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001 Scrip Code: 509079 To, National Stock Exchange of India Lim

5 million

ned for WHO GMP, EU GMP, ANVISA, MHRA, and USFDA standards, it houses: ▪ ▪ ▪ Lyophilized vials – 5 million/month Liquid vials – 6 million/month Ampoules – 10 million/month Built for both domestic and expor

6 million

, MHRA, and USFDA standards, it houses: ▪ ▪ ▪ Lyophilized vials – 5 million/month Liquid vials – 6 million/month Ampoules – 10 million/month Built for both domestic and export markets, it is purpose-engin

10 million

s, it houses: ▪ ▪ ▪ Lyophilized vials – 5 million/month Liquid vials – 6 million/month Ampoules – 10 million/month Built for both domestic and export markets, it is purpose-engineered for complex injectable

30%

gress. 27 more products under development 🟡 18 completed, more lined up; CMO contracts commenced 30% Capacity Utilization FY26 🟡 On-track Global Regulatory Clearance EU GMP & UK MHRA Q1-FY27 US

50%

nd Momentum ➢ Multi-city roadshows expanding reach across key IVF hubs. ➢ Strong YTD performance (>50% YoY growth) with power brands delivering high double digit growth. ➢ Portfolio mix improved towa

rs. 4

for a Rich Innovation Cycle ➢ r-FSH and vaginal microbiome products as near-term scientific triggers. 4. Outlook for Power brands: ➢ Puregraf – On track to become ~INR 25 crore pa brand ➢ Cetrocare – On

INR 25 crore

s as near-term scientific triggers. 4. Outlook for Power brands: ➢ Puregraf – On track to become ~INR 25 crore pa brand ➢ Cetrocare – On track to break into top 3 for the molecule segment ➢ Supergraf – Launched

INR 15

track to break into top 3 for the molecule segment ➢ Supergraf – Launched in 2024, target to become INR 15 crs brand in 2 years ➢ Guficin Alpha – Target to become an INR 10 crore brand 1. Deepening Scientif

INR 10 crore

aunched in 2024, target to become INR 15 crs brand in 2 years ➢ Guficin Alpha – Target to become an INR 10 crore brand 1. Deepening Scientific & Patient-Centric Engagement ➢ CMEs, RTMs and regional/national con

10%

ATAM & ROW) 207.4 176.8 176 104.7 104.2 34.4 16.9 3.7 824.1 ➢ Market Share Goal: Capture 5–10% in identified geographies ➢ Portfolio Expansion: Build on current high-value molecules, adding new

80%

o “hot” tumours, improving immune cell infiltration and long-term tumour regression Demonstrated >80% clearance and abscopal (distant tumour) effects in preclinical mesothelioma models Preclinical E